onpattro 2 mgml
medison pharma ltd - patisiran as sodium - concentrate for solution for infusion - patisiran as sodium 2 mg / 1 ml - patisiran - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy
onpattro patisiran 10 mg/5 ml concentrated injection for infusion vial
alnylam australia pty ltd - patisiran, quantity: 10 mg - injection, concentrated - excipient ingredients: peg2000-c-dmg; sodium chloride; dlin-mc3-dma; water for injections; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; cholesterol; distearoylphosphatidylcholine - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
onpattro
alnylam netherlands b.v. - patisiran sodium - amyloidosis, familial - other nervous system drugs - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
onpattro solution
alnylam netherlands b.v. - patisiran (patisiran sodium) - solution - 2mg - patisiran (patisiran sodium) 2mg - other miscellaneous therapeutic agents
onpattro- patisiran injection, lipid complex
alnylam pharmaceuticals, inc. - patisiran sodium (unii: wo0ym16lkg) (patisiran - unii:50fkx8cb2y) - onpattro is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to onpattro during pregnancy. physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the program by calling 1-877-256-9526 or by contacting alnylampregnancyprogram@iqvia.com. risk summary there are no available data on onpattro use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. onpattro treatment leads to a decrease in serum vitamin a levels, and vitamin a supplementation is advised for patients taking onpattro. vitamin a is essential for normal embryofetal development; however, excessive levels of vitamin a are associated with adverse developmental effects. the effects on the fetus of a reduction in maternal serum ttr caused by onpattro and of vitamin a supplementation are unknown [see
amvuttra
alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - other nervous system drugs - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
amvuttra solution
alnylam netherlands b.v. - vutrisiran (vutrisiran sodium) - solution - 25mg - vutrisiran (vutrisiran sodium) 25mg
anagrelide mylan
mylan pharmaceuticals limited - anagrelide hydrochloride - thrombocythemia, essential - antineoplastic agents - anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (et) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.
ketamine interpharma ketamine (as hydrochloride) 20 mg/2 ml solution for injection ampoule
interpharma pty ltd - ketamine hydrochloride, quantity: 11.53 mg/ml (equivalent: ketamine, qty 10 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - ketamine interpharma? is recommended:,1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine interpharma ? is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.
ketamine interpharma ketamine (as hydrochloride) 100 mg/10 ml solution for injection ampoule
interpharma pty ltd - ketamine hydrochloride, quantity: 11.53 mg/ml (equivalent: ketamine, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - ketamine interpharma? is recommended:,1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine interpharma ? is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.